Agile Therapeutics(AGRX)
搜索文档
Agile Therapeutics(AGRX) - 2020 Q1 - Earnings Call Transcript
2020-05-12 06:57
Agile Therapeutics, Inc. (OTCQB:AGRX) Q1 2020 Earnings Conference Call May 5, 2020 4:30 PM ET Company Participants Matthew Riley - IR Alfred Altomari - Chairman, President & CEO Dennis Reilly - SVP & CFO Conference Call Participants Daniel Busby - RBC Capital Markets Timothy Lugo - William Blair & Company Leland Gershell - Oppenheimer Oren Livnat - H.C. Wainwright & Co. Esther Hong - Janney Montgomery Scott Operator Greetings, and welcome to the Agile Therapeutics First Quarter 2020 Financial Results Confer ...
Agile Therapeutics(AGRX) - 2020 Q1 - Quarterly Report
2020-05-06 04:31
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36464 Agile Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 23-2936302 (State or other ...
Agile Therapeutics(AGRX) - 2019 Q4 - Annual Report
2020-02-21 05:36
Use these links to rapidly review the document Table of Contents Item 8. Financial Statements and Supplementary Data Title of each class Trading Symbol(s) Name of exchange on which registered: Common stock, par value $0.0001 per share AGRX The Nasdaq Capital Market Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2019 OR o TRANSITION REPORT ...
Agile Therapeutics(AGRX) - 2019 Q3 - Quarterly Report
2019-10-28 19:32
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36464 Agile Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 23-2936302 (State or o ...
Agile Therapeutics(AGRX) - 2019 Q2 - Quarterly Report
2019-08-01 20:17
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36464 Agile Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 23-2936302 (State or other ...
Agile Therapeutics(AGRX) - 2019 Q1 - Quarterly Report
2019-05-04 04:30
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36464 Agile Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 23-2936302 (State or other ...
Agile Therapeutics(AGRX) - 2018 Q4 - Annual Report
2019-03-13 04:29
Use these links to rapidly review the document Table of Contents Item 8. Financial Statements and Supplementary Data Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2018 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36464 Agile Ther ...